| NCT ID | NCT07248176 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bioray Laboratories |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2025-04-10 |
| Primary Completion | 2027-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6 participants in total. It began in 2025-04-10 with a primary completion date of 2027-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Eligibility Criteria
Inclusion Criteria: 1. Expected survival of at least 3 months; 2. Subjects should have measurable disease that meets the IMWG 2016 criteria; 3. Previously received at least two lines of prior anti-myeloma therapy ； 4. Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ； 5. BCMA positive； 6. ECOG score 0-1； 7. No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. History of other malignant tumors; 3. Active autoimmune diseases requiring immunotherapy; 4. Previously received allogeneic stem cell transplantation; 5. Previous use of CAR-T cells or other genetically modified T cell therapies; 6. Previously received targeted BCMA therapy; 7. Severe cardiovascular disease; 8. Active infection; 9. Positive virology test; 10. Clinically significant central nervous system (CNS) diseases or pathological changes.
Contact & Investigator
Ping Li, PhD
STUDY DIRECTOR
13564181131
Frequently Asked Questions
Who can join the NCT07248176 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07248176 currently recruiting?
Yes, NCT07248176 is actively recruiting participants. Contact the research team at lilyforever76@126.com for enrollment information.
Where is the NCT07248176 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07248176 clinical trial?
NCT07248176 is sponsored by Bioray Laboratories. The principal investigator is Ping Li, PhD at 13564181131. The trial plans to enroll 6 participants.